SHR-8068 Injection

DRUG4 trials

Sponsors

Shanghai Hengrui Pharmaceutical Co., Ltd., Suzhou Suncadia Biopharmaceuticals Co., Ltd.

Conditions

Advanced Biliary Tract CancerAdvanced Urothelial CarcinomaColorectal CancerGastric CancerGastroesophageal-junction Cancer

Phase 1

A Trial of SHR-A2102 With Antitumor Therapy in Advanced Urothelial Carcinoma

RecruitingNCT06639347

Shanghai Hengrui Pharmaceutical Co., Ltd.Advanced Urothelial Carcinoma

Start: 2024-11-04End: 2027-05-31Target: 90Updated: 2024-11-18

Phase 2

A Phase II Study of SHR-8068 Injection in Combination With Anti-tumor Therapies in Colorectal Cancer

RecruitingNCT07071714

Suzhou Suncadia Biopharmaceuticals Co., Ltd.Colorectal Cancer

Start: 2025-07-22End: 2031-10-01Target: 200Updated: 2026-03-18

A Trial of Adebrelimab Plus (SHR-A1811/SHR-A1904 With Chemotherapy) or SHR-8068 as Treatment for Gastric/GEJ Cancer

RecruitingNCT07110571

Suzhou Suncadia Biopharmaceuticals Co., Ltd.Gastric Cancer, Gastroesophageal-junction Cancer

Start: 2025-08-28End: 2027-05-31Target: 200Updated: 2026-01-09

Phase 3

A Phase III Study of SHR-8068 in Combination With Adebrelimab and Platinum-Containing Chemotherapy Versus Durvalumab in Combination With Platinum-Containing Chemotherapy as First-line Treatment for Advanced Biliary Tract Cancer (BTC)

RecruitingNCT07229625

Suzhou Suncadia Biopharmaceuticals Co., Ltd.Advanced Biliary Tract Cancer

Start: 2026-01-21End: 2029-12-01Target: 604Updated: 2026-01-28